Is Valneva SE (INRLF) a Buy, Sell, or Hold?
OTC : INRLF
Valneva SE
$2.62 USD
$0 (0.0%)
- Volume
- 89
- Average Volume
- 175
- Market Capitalization
- $496.87M
- P/E Ratio
- -2.60
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $6.28
- Year Low
- $2.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.14
Company Overview
OTC
Thomas Lingelbach
Biotechnology
Healthcare
INRLF
674
FR
USD
Liquidity Metrics
2.73
2.14
1.60
1.12
0.00
Sales & Valuation
$174.66M
2.56
4.74
-5.79
-0.40
Profitability
-$0.68
-$115.19M
-88.30%
-88.03%
-106.22%
-37.10%
P/E Metrics
-2.60
0.05
0.05
Analyst Price Target & Rating
1/5
1 Analysts
%
Financial Health Scores
-1.96
1/9
$107.63M
$373.43M
$296.44M
-$105.4M
Key Metrics (TTM)
$504.58M
3.23
-5.83
2.14
-106.22%
-36.00%
-38.00%
-17.27%
119 days
Company Executives
| Name | Title |
|---|---|
| Hanneke Schuitemaker | Chief Scientific Officer |
| Joshua Drumm | Vice President of Investor Relations |
| Peter Buhler | Chief Financial Officer |
| Thomas Lingelbach | President, Chief Executive Officer & Director |
| Vincent Dequenne | Chief Operating Officer |
| Laetitia Bachelot-Fontaine | Vice President of Global Communications & European Investor Relations |
| Petra Pesendorfer | Chief People Officer |
| Juan-Carlos Jaramillo | Chief Medical Officer |
| Dipal Patel | Chief Commercial Officer |
| Kendra Wergin | General Counsel & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Valneva SE (OTC:INRLF) Stock
Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization designed to actively protect against Japanese encephalitis. Another key product is DUKORAL, an oral vaccine intended to prevent diarrhea caused by Vibrio cholera and/or the heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also developed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva is advancing VLA15, a Lyme disease vaccine candidate that has successfully completed Phase II clinical ... trials. Furthermore, VLA1553, a candidate vaccine against the chikungunya virus, is currently undergoing Phase III clinical evaluation. Valneva distributes its products globally, with a market presence spanning the United States, Canada, Germany, Austria, the Nordic region, the United Kingdom, other European countries, and various international territories. The company has established significant strategic collaborations, including a partnership with Pfizer, Inc. to jointly develop and commercialize its Lyme disease vaccine. It also collaborates with Instituto Butantan on the development, manufacturing, and marketing of a single-dose chikungunya vaccine. Founded in 1998, Valneva SE is headquartered in Saint-Herblain, France.
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
2026-05-13 13:01:08
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
2026-05-05 12:30:00
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Regulated market of Euronext Paris - Compartment B
Frequently Asked Questions
-
What is the current Valneva SE (INRLF) stock price?
-
Valneva SE(OTC:INRLF) stock price is $2.62 in the last trading session. During the trading session, INRLF stock reached the peak price of $6.28 while $2.46 was the lowest point it dropped to. The percentage change in INRLF stock occurred in the recent session was 0.0% while the dollar amount for the price change in INRLF stock was $0.
-
INRLF's industry and sector of operation?
-
The OTC listed INRLF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INRLF?
-
Hanneke Schuitemaker | Chief Scientific Officer
Joshua Drumm | Vice President of Investor Relations
Peter Buhler | Chief Financial Officer
Thomas Lingelbach | President, Chief Executive Officer & Director
Vincent Dequenne | Chief Operating Officer -
How many employees does INRLF have?
-
Number of INRLF employees currently stands at 674. INRLF operates from 6 rue Alain Bombard, Saint-Herblain, GE 44800, FR.
-
Link for INRLF official website?
-
Official Website of INRLF is: https://valneva.com
-
How do I contact INRLF?
-
INRLF could be contacted at phone #33 2 28 07 37 10 and can also be accessed through its website. INRLF operates from 6 rue Alain Bombard, Saint-Herblain, GE 44800, FR.
-
How many shares of INRLF are traded daily?
-
The average number of INRLF shares traded daily for last 3 months was 175.
-
What is the market cap of INRLF currently?
-
The market value of INRLF currently stands at $496.87M with its latest stock price at $2.62